vs
Side-by-side financial comparison of EMERSON RADIO CORP (MSN) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
EMERSON RADIO CORP is the larger business by last-quarter revenue ($1.9M vs $1.3M, roughly 1.5× RELMADA THERAPEUTICS, INC.). On growth, RELMADA THERAPEUTICS, INC. posted the faster year-over-year revenue change (13.0% vs -52.8%). Over the past eight quarters, RELMADA THERAPEUTICS, INC.'s revenue compounded faster (95.4% CAGR vs -7.3%).
Emerson Radio Corporation is one of the United States' largest volume consumer electronics distributors and has a recognized trademark in continuous use since 1912. The company designs, markets, and licenses many product lines worldwide, including products sold, and sometimes licensed, under the brand name G Clef, an homage to Emerson's logo.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
MSN vs RLMD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.9M | $1.3M |
| Net Profit | $-694.0K | — |
| Gross Margin | 10.9% | — |
| Operating Margin | -43.7% | -2130.6% |
| Net Margin | -36.7% | — |
| Revenue YoY | -52.8% | 13.0% |
| Net Profit YoY | -31.7% | — |
| EPS (diluted) | $-0.03 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.9M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.7M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $2.7M | — | ||
| Q2 24 | $2.2M | — | ||
| Q1 24 | $2.2M | — |
| Q4 25 | $-694.0K | — | ||
| Q3 25 | $-1.0M | — | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-2.4M | — | ||
| Q4 24 | $-527.0K | — | ||
| Q3 24 | $-881.0K | — | ||
| Q2 24 | $-962.0K | — | ||
| Q1 24 | $-883.0K | — |
| Q4 25 | 10.9% | — | ||
| Q3 25 | -0.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | -3.0% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 9.9% | — | ||
| Q2 24 | 8.8% | — | ||
| Q1 24 | 15.9% | — |
| Q4 25 | -43.7% | — | ||
| Q3 25 | -98.4% | — | ||
| Q2 25 | -78.1% | — | ||
| Q1 25 | -137.8% | — | ||
| Q4 24 | -18.3% | — | ||
| Q3 24 | -40.8% | — | ||
| Q2 24 | -55.6% | — | ||
| Q1 24 | -52.2% | — |
| Q4 25 | -36.7% | — | ||
| Q3 25 | -85.8% | — | ||
| Q2 25 | -68.1% | — | ||
| Q1 25 | -127.9% | — | ||
| Q4 24 | -13.2% | — | ||
| Q3 24 | -32.2% | — | ||
| Q2 24 | -43.8% | — | ||
| Q1 24 | -40.1% | — |
| Q4 25 | $-0.03 | — | ||
| Q3 25 | $-0.05 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $-0.10 | — | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $-0.04 | — | ||
| Q2 24 | $-0.05 | — | ||
| Q1 24 | $-0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.3M | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $18.6M | $85.4M |
| Total Assets | $20.1M | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.3M | — | ||
| Q3 25 | $13.5M | — | ||
| Q2 25 | $15.5M | — | ||
| Q1 25 | $16.1M | — | ||
| Q4 24 | $16.4M | — | ||
| Q3 24 | $16.7M | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | $19.9M | — |
| Q4 25 | $18.6M | — | ||
| Q3 25 | $19.3M | — | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | $21.5M | — | ||
| Q4 24 | $23.9M | — | ||
| Q3 24 | $24.4M | — | ||
| Q2 24 | $25.3M | — | ||
| Q1 24 | $26.2M | — |
| Q4 25 | $20.1M | — | ||
| Q3 25 | $20.7M | — | ||
| Q2 25 | $23.3M | — | ||
| Q1 25 | $23.5M | — | ||
| Q4 24 | $26.4M | — | ||
| Q3 24 | $26.6M | — | ||
| Q2 24 | $28.5M | — | ||
| Q1 24 | $29.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-228.0K | $-10.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-228.0K | — | ||
| Q3 25 | $-2.0M | — | ||
| Q2 25 | $-514.0K | — | ||
| Q1 25 | $-391.0K | — | ||
| Q4 24 | $-293.0K | — | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-840.0K | — | ||
| Q1 24 | $-2.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-301.0K | — | ||
| Q3 24 | $-2.1M | — | ||
| Q2 24 | $-1.0M | — | ||
| Q1 24 | $-2.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -7.5% | — | ||
| Q3 24 | -77.8% | — | ||
| Q2 24 | -46.4% | — | ||
| Q1 24 | -102.3% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 8.2% | — | ||
| Q1 24 | 0.5% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MSN
| Products | $1.8M | 95% |
| Other | $87.0K | 5% |
RLMD
Segment breakdown not available.
